Bioequivalence of a New Sublingual and a Reference Alprazolam Immediate Release Tablet Formulation

• Status: Withdrawn
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study tests the assumption that the bioavailability of alprazolam from a new sublingual formulation is the same as that from an existing commercial immediate release tablet formulation.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Alprazolam

Criteria

Inclusion Criteria:

• Healthy male or female subjects

• BMI 17.5 - 30.5

• Must provide informed consent

Exclusion Criteria:

• Clinically significant disease

• Narrow angle glaucoma

• Positive drug screen